An Open-label, Phase II, Randomized, Pilot Study to Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Change in hemoglobin levels
Difference in proportion of patients achieving an erythroid response within 12 weeks of treatment between the two arms according to modified IWG 2006 criteria (increase in Hb ≥ 1.5 g/dL)
Within 12 weeks
United States: Food and Drug Administration
|Bon Secours St. Francis Hospital||Greenville, South Carolina 29601|
|Rush University Medical Center Rush University||Chicago, Illinois 60612|